Related Experiment Video
Updated: Jun 1, 2026
10:03
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Elevated B-type natriuretic peptide levels in patients undergoing coronary stenting
Abhay Krishna1, Aditya Kapoor, Sudeep Kumar
1Department of Cardiology, Sanjay Gandhi PGIMS, Lucknow, India.
The Journal of Invasive Cardiology
|June 8, 2011
Summary
B-type natriuretic peptide (BNP) levels significantly increase after percutaneous coronary intervention (PCI), especially in patients with acute coronary syndrome (ACS). These BNP changes following PCI offer prognostic insights across the ACS spectrum.
Area of Science:
- Cardiology
- Biomarkers
- Interventional Cardiology
Background:
- B-type natriuretic peptide (BNP) release can be triggered by tissue hypoxia, independent of left ventricular (LV) dysfunction.
- Interest in BNP changes post-percutaneous coronary intervention (PCI) is growing, yet most studies focus on single pre-procedural levels.
- Previous research on BNP elevation after coronary stenting yielded conflicting results, often excluding acute coronary syndrome (ACS) patients.
Purpose of the Study:
- To investigate changes in BNP levels following coronary stenting in a diverse patient cohort.
- To assess the prognostic significance of BNP variations across the spectrum of ACS.
- To identify predictors of elevated BNP levels before and after PCI.
Main Methods:
- Studied 100 patients undergoing coronary stenting, encompassing the full range of ACS.
- Measured B-type natriuretic peptide (BNP) levels pre- and post-procedure.
- Analyzed correlations between BNP changes and clinical, angiographic, and procedural factors.
Main Results:
- A significant rise in BNP was observed post-stenting in 100 ACS patients.
- Baseline BNP > 100 pg/ml was found in 31%, rising to 45% post-PCI.
- Elevated post-PCI BNP was linked to recent ACS, LV dysfunction, high troponin I, angiographic thrombus, and lower post-PCI flow (TIMI 1-2).
Conclusions:
- Recent ACS, elevated baseline troponin, LV dysfunction, and angiographic thrombus predict high BNP levels pre- and post-PCI.
- Recent ACS is the strongest predictor of elevated BNP.
- BNP levels increased post-PCI even in patients with stable angina.
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:30Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
01:30Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...